BB BIOTECH N

Last trading week, numerous analysts advised exiting various stocks and issued multiple sell recommendations. At the same time, BB Biotech reported a stronger comeback with solid quarterly results and a portfolio that outperforms the industry index, while the stock still lags its intrinsic value. » Plus sur finanzen.net

BB Biotech recorded a NAV increase of 17.2% in CHF/eur (15.9% in USD) in Q2 and a quarterly profit of CHF 451m versus a loss in the prior year. The portfolio outperformed the Nasdaq Biotechnology Index by 3.5 percentage points, while the stock returned 9.7% and lagged the intrinsic value, with the discount widening to 12.9%. Management accelerated the realignment (12 new additions in the quarter) and increased weightings in large biotech names such as Amgen, Argenx, Vertex and Gilead; about 7% of NAV is held in liquid assets. Additional tailwinds come from recent sector takeovers and a new distribution policy (target yield 3–5%, first payment spring 2027); risks remain from price regulation, interest rates and clinical failures. » Plus sur finanzen.net

BB Biotech posted a profit of CHF 451 million in Q2 2026, after a year‑earlier loss of CHF 100 million and a loss of CHF 21 million in Q1 2026. Drivers included extensive M&A activity and positive share price movements in the portfolio; the stock delivered a total return of 9.7% in CHF. NAV rose 17.2% in CHF and EUR (15.9% in USD). The company reported twelve new investments and announced M&A transactions, expanded its investment analysis with an AI‑powered platform, and adjusted its dividend policy to target a 3–5% annual dividend yield, with the first payout scheduled for spring 2027. » Plus sur finanzen.net